TRC-150094

TRC-150094 (International Nonproprietary Name: omzotirome) is a synthetic functional analog of the endogenous thyroid hormone metabolite 3,5-diiodothyronine (T2), distinguished from classical thyroid hormone receptor (TR) agonists by its receptor-independent mechanism of action at the mitochondrial level. Developed at the Torrent Research Centre (Torrent Pharmaceuticals Ltd., Ahmedabad, India), the compound belongs structurally to the indene-pyrazole-propionic acid class and exerts its principal pharmacological effects through direct activation of sirtuin 1 (SIRT1) in hepatic and skeletal muscle tissue, with downstream deacetylation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha) and sterol regulatory element-binding protein 1c (SREBP-1c), leading to upregulation of mitochondrial biogenesis genes and downregulation of lipogenic transcriptional programs. The net metabolic consequence is increased mitochondrial respiration, increased fatty acid import and oxidation in liver and skeletal muscle, increased energy expenditure, and restoration of metabolic flexibility in states of caloric excess and insulin resistance. Unlike the thyroid hormone receptor beta-selective agonists resmetirom, eprotirome, and sobetirome, TRC-150094 has very low potency at both TRalpha1 and TRbeta1 isoforms and does not produce the cardiac, skeletal, or hypothalamic-pituitary-thyroid axis suppression that has historically limited thyromimetic drug development.

Preclinical pharmacology in high-fat diet rat models demonstrated a 24 percent increase in energy expenditure, normalization of body weight gain to chow-fed control levels, a 56 percent increase in hepatic mitochondrial fatty acid import, a 32 percent increase in hepatic fatty acid oxidation, and a muscle fiber type shift toward the oxidative phenotype, with reductions in plasma cholesterol, triglycerides, and visceral adiposity [1, 2]. In obese ZSF1 rats (a model of concurrent obesity, type 2 diabetes, hypertension, and nephropathy), chronic TRC-150094 administration at 12 mg/kg in the published literature for 24 weeks attenuated the progression of hyperglycemia, hypertension, hepatic steatosis, and glomerulosclerosis, with significant increases in hepatic and skeletal muscle state 3 mitochondrial respiration and fatty acid oxidation capacity [3].

A Phase 1 single- and multiple-ascending-dose trial in 86 overweight and obese subjects established a pharmacokinetic profile suitable for once-daily oral dosing, with rapid absorption (Tmax 0.25 to 4 hours), dose-proportional systemic exposure across 5 to 400 mg, a terminal elimination half-life of 13 to 18 hours, and predominant metabolism through Phase II conjugation reactions (glucuronidation and sulfation) independent of cytochrome P450 enzymes [4]. A Phase 2 multicenter, double-blind, placebo-controlled trial in 225 overweight or obese diabetic subjects with dyslipidemia demonstrated that TRC-150094 at 25 to 50 mg daily for 24 weeks reduced fasting plasma glucose by 13.9 to 21.7 mg/dL, reduced fasting insulin, improved HOMA-IR by 2.0 to 2.5 units, reduced mean arterial pressure by 3.1 to 4.2 mmHg, and produced favorable trends in atherogenic lipid fractions, with a weight-neutral profile and no treatment-related hypoglycemia [5]. A separate randomized controlled trial of 50 mg daily in 40 male cardiometabolic patients at two sites (India and the Netherlands), however, did not demonstrate improvement in insulin sensitivity by hyperinsulinemic euglycemic clamp at 28 days [6]. The compound is currently in a Phase 3 multinational trial (NCT03254446) evaluating 45 mg daily versus placebo in 1250 subjects with concurrent diabetes, dyslipidemia, and hypertension, with co-primary endpoints of HbA1c, mean arterial pressure, and non-HDL cholesterol reduction over 24 weeks with a 26-week safety extension.

TRC-150094 has been well tolerated across all completed clinical studies, with adverse events that are mild to moderate, non-dose-dependent, and not requiring treatment discontinuation. The compound does not suppress the hypothalamic-pituitary-thyroid axis and does not produce clinically significant changes in thyroid-stimulating hormone, free triiodothyronine, or free thyroxine at studied doses. This monograph documents the chemistry, structural class, and synthesis of TRC-150094; the receptor-independent mitochondrial mechanism of action through SIRT1 activation and downstream transcriptional regulation; the comprehensive pharmacokinetic record; preclinical pharmacology in high-fat diet and diabetic-obese rodent models; the clinical evidence base across Phase 1, Phase 2, and Phase 3 programs; sourcing and quality verification for research applications; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a structured comparative assessment of five thyromimetic and mitochondrial modulator compounds against TRC-150094 on five competency standards. The compound is not approved by any regulatory authority. It is available as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.